FDA Clears IND for One-Time Hemophilia A Gene Editing Therapy; Cash Runway Into 2028
MGX sits 20% above its 52-week low of $0.6.
Summary
The FDA cleared Metagenomi's IND for MGX-001, its wholly owned hemophilia A gene editing program, letting the company start its first-in-human INTEGR8 Phase 1/2 trial. That is the key de-risking step for a micro-cap with no revenue-generating product; the program now moves from preclinical to clinic. Management plans to start INTEGR8 in the first half of 2027 and report initial safety, tolerability and FVIII activity data in the second half of 2027. Cash and marketable securities stood at $101.7 million on September 30, down from $160.8 million at year-end, with runway guided into 2028 — enough to fund the trial start but not its readout without more capital. Q3 R&D spend fell to $17.5 million from $25.3 million a year earlier, the net loss was $21.1 million, and revenue was $2.18 million. Additional preclinical MGX-001 data will be presented at ASH on December 14, 2026.
At the time of this announcement, MGX was trading at $0.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $0.60 to $2.28. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.